 |
|
Amphetamines reverse Parkinson's disease symptoms in mice
August 02, 2005Durham, N.C. - Amphetamines, including the drug popularly known as Ecstasy, can reverse the symptoms of Parkinson's disease in mice with an acute form of the condition, according to new research at Duke University Medical Center.
The researchers caution that the findings in animals do not suggest Parkinson's disease patients should find relief by taking amphetamines, which are drugs of abuse with many dangerous side effects. The findings rather indicate that drugs with similar chemical attributes might offer useful alternatives to current therapies, the researchers said.
The new study also shows that amphetamines - normally thought to act by increasing dopamine concentrations in the brain -- correct the behavioral abnormalities associated with Parkinson's in mice devoid of the brain messenger. Dopamine normally acts on dopamine receptors -- protein switches on the surface of neurons - to stimulate brain processes that affect movement, emotion, pleasure and mood.
Parkinson's disease stems from the degeneration of neurons in a brain region that controls movement. That degeneration, in turn, leads to a shortage of the chemical messenger dopamine. The finding that amphetamines can alter movement independently of dopamine opens up new directions in the search for prospective anti-Parkinsonian drugs, the researchers said.
The researchers, led by James B. Duke professor of cell biology Marc Caron, Ph.D. and Assistant Research Professor Raul Gainetdinov, M.D., Ph.D., of Duke, made the discovery after testing the utility of more than 60 compounds for reversing Parkinson's symptoms in a mouse model of the disease. Developed by the Duke team, the mice lack detectable brain levels of dopamine and experience essentially all the symptoms of Parkinson's disease for several hours before recovering their normal behavior. Caron is also a researcher of the Duke Institute for Genome Sciences & Policy.
The team reports its findings in the August 2005 issue of Public Library of Science (PLoS) Biology. The research was sponsored by the National Institutes of Health and a donation from The Long Island Community Foundation, a division of The New York Community Trust.
"This model is exciting because it allows us to examine the potential contribution of systems other than dopamine to Parkinson's disease," said Caron. "We may be able to discover avenues for treatment that had never been thought about before or that were impossible to investigate."
The new mouse model enables the researchers to acutely eliminate dopamine, exposing systems contributing to the disease that may not have been obvious before, he explained. The severity of disease symptoms in the mice also provides a very sensitive test for compounds with potential therapeutic value, the researchers said.
In the United States, at least 500,000 people suffer from Parkinson's disease, and about 50,000 new cases are reported annually, according to the National Institute of Neurological Disorders and Stroke. These figures are expected to rise as the average age of the population increases. Symptoms of the disease include tremors, slow movement or an inability to move, rigid limbs and a shuffling gait. Progression of the disease also leads to severe impairment in cognitive function.
Dopamine replacement therapy which involves administration of the dopamine precursor, L-DOPA, remains the gold standard for Parkinson's treatment, said Tatyana Sotnikova, Ph.D., of Duke. However, the efficacy of the therapy wanes with time, and patients often develop fluctuations in motor performance and other adverse reactions.
In the current study, the researchers treated mice unable to recycle dopamine with a drug that also prevented them from manufacturing the brain messenger. The brains of the mice therefore lack detectable levels of dopamine and the animals exhibit all the symptoms of Parkinson's disease for up to 16 hours. Those symptoms included severely impaired movement, rigidity and tremor. When treated with L-DOPA, the symptoms disappeared as the animals resumed normal movement.
Surprisingly, the researchers reported, treating mice lacking dopamine with high doses of amphetamine derivatives - including methamphetamine and MDMA, otherwise known as Ecstasy - reversed those symptoms. Ecstasy was most effective at counteracting the manifestations of Parkinson's symptoms in the mice, with the beneficial effects becoming more pronounced with increasing dose.
The researchers also report that low doses of amphetamines could, when combined with L-DOPA, potentiate minimally effective doses of L-DOPA in the mice. This could have important considerations in reducing some of the side effects of current therapy.
"The locomotor stimulating effect of amphetamine and its derivatives are classically thought to result from a massive flood of dopamine," said Sotnikova. "However, the mice have only a tiny fraction of dopamine, which cannot be recycled, precluding a rise in dopamine as the possible mechanism.
"Taken together, the findings indicate that Ecstasy can improve movement control independently of dopamine and, most importantly provide evidence that drug activation of other neuronal pathways may be sufficient to restore movement even in the virtual absence of dopamine neurotransmission," she added.
Amphetamines might reverse the animal's symptoms through their effects on a different group of receptors called trace amine receptors, the researchers suggested. Recent evidence showed that amphetamines act on trace amine receptors in addition to dopamine transmission, yet little is known about their physiological role in mammals.
The current findings are particularly promising given the severity of symptoms in the mice completely lacking dopamine, said Gainetdinov. "We think that this new animal model provides a much more stringent test for potential drugs that might prove efficacious in patients with Parkinson's disease."
Many of the previously developed animal models of Parkinson's disease have reduced, but detectable, levels of dopamine and do not show all the characteristics of Parkinson's disease, making studies of potential therapeutic methods in those animals less clear, Gainetdinov said. On the other hand, animals permanently lacking dopamine cannot survive, he added.
While the results are promising, the researchers cautioned, Ecstasy's ability to stimulate movement in the mice occurred only with high doses of the drug. Such high doses might destroy nerve tissue in normal mice and in humans, who are generally more sensitive than mice to such drugs.
"Amphetamines are controversial drugs, and there's no reason to suggest that amphetamines themselves should be used to treat Parkinson's," Gainetdinov said. "However, the chemical structure of amphetamines may lead to new, amphetamine-like drugs, that might provide a more lasting and beneficial alternative to L-DOPA in the treatment of Parkinson's disease.\\\
Duke University Medical Center
Parkinson's disease stems from the degeneration of neurons in a brain region that controls movement. That degeneration, in turn, leads to a shortage of the chemical messenger dopamine. The finding that amphetamines can alter movement independently of dopamine opens up new directions in the search for prospective anti-Parkinsonian drugs, the researchers said.
The researchers, led by James B. Duke professor of cell biology Marc Caron, Ph.D. and Assistant Research Professor Raul Gainetdinov, M.D., Ph.D., of Duke, made the discovery after testing the utility of more than 60 compounds for reversing Parkinson's symptoms in a mouse model of the disease. Developed by the Duke team, the mice lack detectable brain levels of dopamine and experience essentially all the symptoms of Parkinson's disease for several hours before recovering their normal behavior. Caron is also a researcher of the Duke Institute for Genome Sciences & Policy.
The team reports its findings in the August 2005 issue of Public Library of Science (PLoS) Biology. The research was sponsored by the National Institutes of Health and a donation from The Long Island Community Foundation, a division of The New York Community Trust.
"This model is exciting because it allows us to examine the potential contribution of systems other than dopamine to Parkinson's disease," said Caron. "We may be able to discover avenues for treatment that had never been thought about before or that were impossible to investigate."
The new mouse model enables the researchers to acutely eliminate dopamine, exposing systems contributing to the disease that may not have been obvious before, he explained. The severity of disease symptoms in the mice also provides a very sensitive test for compounds with potential therapeutic value, the researchers said.
In the United States, at least 500,000 people suffer from Parkinson's disease, and about 50,000 new cases are reported annually, according to the National Institute of Neurological Disorders and Stroke. These figures are expected to rise as the average age of the population increases. Symptoms of the disease include tremors, slow movement or an inability to move, rigid limbs and a shuffling gait. Progression of the disease also leads to severe impairment in cognitive function.
Dopamine replacement therapy which involves administration of the dopamine precursor, L-DOPA, remains the gold standard for Parkinson's treatment, said Tatyana Sotnikova, Ph.D., of Duke. However, the efficacy of the therapy wanes with time, and patients often develop fluctuations in motor performance and other adverse reactions.
In the current study, the researchers treated mice unable to recycle dopamine with a drug that also prevented them from manufacturing the brain messenger. The brains of the mice therefore lack detectable levels of dopamine and the animals exhibit all the symptoms of Parkinson's disease for up to 16 hours. Those symptoms included severely impaired movement, rigidity and tremor. When treated with L-DOPA, the symptoms disappeared as the animals resumed normal movement.
Surprisingly, the researchers reported, treating mice lacking dopamine with high doses of amphetamine derivatives - including methamphetamine and MDMA, otherwise known as Ecstasy - reversed those symptoms. Ecstasy was most effective at counteracting the manifestations of Parkinson's symptoms in the mice, with the beneficial effects becoming more pronounced with increasing dose.
The researchers also report that low doses of amphetamines could, when combined with L-DOPA, potentiate minimally effective doses of L-DOPA in the mice. This could have important considerations in reducing some of the side effects of current therapy.
"The locomotor stimulating effect of amphetamine and its derivatives are classically thought to result from a massive flood of dopamine," said Sotnikova. "However, the mice have only a tiny fraction of dopamine, which cannot be recycled, precluding a rise in dopamine as the possible mechanism.
"Taken together, the findings indicate that Ecstasy can improve movement control independently of dopamine and, most importantly provide evidence that drug activation of other neuronal pathways may be sufficient to restore movement even in the virtual absence of dopamine neurotransmission," she added.
Amphetamines might reverse the animal's symptoms through their effects on a different group of receptors called trace amine receptors, the researchers suggested. Recent evidence showed that amphetamines act on trace amine receptors in addition to dopamine transmission, yet little is known about their physiological role in mammals.
The current findings are particularly promising given the severity of symptoms in the mice completely lacking dopamine, said Gainetdinov. "We think that this new animal model provides a much more stringent test for potential drugs that might prove efficacious in patients with Parkinson's disease."
Many of the previously developed animal models of Parkinson's disease have reduced, but detectable, levels of dopamine and do not show all the characteristics of Parkinson's disease, making studies of potential therapeutic methods in those animals less clear, Gainetdinov said. On the other hand, animals permanently lacking dopamine cannot survive, he added.
While the results are promising, the researchers cautioned, Ecstasy's ability to stimulate movement in the mice occurred only with high doses of the drug. Such high doses might destroy nerve tissue in normal mice and in humans, who are generally more sensitive than mice to such drugs.
"Amphetamines are controversial drugs, and there's no reason to suggest that amphetamines themselves should be used to treat Parkinson's," Gainetdinov said. "However, the chemical structure of amphetamines may lead to new, amphetamine-like drugs, that might provide a more lasting and beneficial alternative to L-DOPA in the treatment of Parkinson's disease.\\\
Duke University Medical Center
Amphetamines Current Events and Amphetamines News RSSCaltech scientists engineer supersensitive receptor, gain better understanding of dopamine system
Genetically modifying a receptor found on the neurons that produce the neurotransmitter dopamine has given California Institute of Technology (Caltech) researchers a unique glimpse into the workings of the brain's dopamine system--as well as a new target for treating diseases that result from either too much or too little of this critical neurotransmitter.
1 sleepless night increases dopamine in the human brain
Just one night without sleep can increase the amount of the chemical dopamine in the human brain, according to new imaging research in the August 20 issue of The Journal of Neuroscience.
N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
PET imaging focuses on medication's purported ability to improve mental performance
Concerned by the growing numbers of people using stimulant medications such as methylphenidate (MP)-either legally or illegally-to improve attention and focus, researchers used positron emission tomography (PET) imaging with the radiotracer fluorodeoxyglucose (FDG) to assess the effects of the drug on brain function in the normal human brain.
Study finds link between amphetamine abuse and heart attacks in young adults
Young adults who abuse amphetamines may be at greater risk of suffering a heart attack, UT Southwestern Medical Center researchers have found.
Animal research suggests new strategy for treating cocaine addiction
New research in monkeys suggests the feasibility of treating cocaine addiction with a "replacement" drug that mimics the effects of cocaine but has less potential for abuse - similar to the way nicotine and heroin addictions are treated.
Chilean authors, publishing in Science, discover drug-craving brain region in rats
Chilean researchers have identified a region of the brain - the insular cortex - that plays a role in drug craving in amphetamine-addicted rats, according to a report published in the 26 October issue of the journal Science, published by the American Association for the Advancement of Science (AAAS), the nonprofit science society.
Insulin signaling and amphetamines
Abuse of psychostimulants such as amphetamine remains a serious public health concern. Amphetamines mediate their behavioral effects by stimulating dopaminergic signaling throughout reward circuits of the brain.
Research Examines the Connection Between Substance Abuse and Violence
Approximately 50 percent of Americans over the age of 12 currently drink alcohol, according to a 2003 report by the Substance Abuse and Mental Health Services Administration.
Brain-boosting pill alleviates post-chemotherapy fogginess
A drug described by some people as a "genius pill" for enhancing cognitive function provided relief to a small group of Rochester breast cancer survivors who were coping with a side effect known as "chemo-brain," according to a University of Rochester Medical Center study.
More Amphetamines Current Events and Amphetamines News Articles
 | On Speed: The Many Lives of Amphetamine by Nicolas Rasmussen "Rasmussen, who has taught life sciences and medicine at UCLA and other universities, examines amphetamine as a case study on the place drugs occupy in our culture and our fantasies (of miracle cures and elixirs). The story begins with chemist Gordon Alles’s creation of amphetamine in 1929 and continues through its use for weight loss, attention deficit disorders and today’s crystal meth... |
 | Speed, Ecstasy, Ritalin: The Science of Amphetamines by Leslie Iversen Amphetamines have had a relatively short, though chequered history. From their use in wartime, their abuse by the beat generation, up to the popularity of Ecstasy in the late 20th century, many have found amphetamines an enjoyable, though unpredictable, stimulant. More than that though, amphetamine-based treatments have been found to have beneficial effects for those suffering from attention... |
 | Amphetamine Syntheses: Industrial by Otto Snow Amphetamine Syntheses (1998) was a global blockbuster. The new and improved Industrial edition is now available, jam packed with state of the art drug chemistry, hot new formulas written by some of the greatest minds of the 20th century. Small town mom and pop labs across America to the multi-ton labs of global organized crime, how they make drugs and what they use to make them. Otto has put... |
 | Secrets of Methamphetamine Manufacture: Including Recipes for Mda, Ecstasy, and Other Psychedelic Amphetamines by Uncle Fester For nearly 20 years now I have been training champions, the champions of the field of clandestine chemistry. This book is their training ground. I cover virtually every possible method of making that "food of the God's" - meth along with how to make it from commonplace materials. I also give coverage of the history of this field, so that newcomers can quickly feel like old pros. ... |
 | Advanced Techniques of Clandestine Psychedelic & Amphetamine Manufacture by Uncle Fester |
 | Amphetamine Misuse: International Perspectives on Current Trends by KLEE Drug abuse is now a global problem, affecting the health and safety of individuals and threatening the stability and economies of nations. The pandemic of drug abuse shows no sign of abating despite the vigorous and costly attempts to control the supply of illicit drugs which have been sustained over many years.The abuse of amphetamines has long been neglected by authorities whose attention,... |
| Amphetamines: Danger in the Fast Lane (The Encyclopedia of Psycoactive Drugs) by Scott E., Ph.D. Lukas, Solomon H. Snyder, Barry L. Jacobs Examines the history, effects, and medical and legal aspects of amphetamine use and... | |
| Speed Culture: Amphetamine Use and Abuse in America (Harvard Paperbacks) by Lester Grinspoon, Peter Hedblom | |
 | Amphetamine Syntheses Overview & Reference Guide for Professionals by Otto Snow the most comprehensive reference guide on the syntheses of amphetamines, phenyethylamines, ephedrine, cathinone, their immediate precursors and precursors. This includes the syntheses of mescaline and all popular psychedelic amphetamines including MDMA, MDEA, 2CB, TMA, DOB, DOM etc. Hundreds of reactions are described including a review of the Controlled Substance Analogue Act. ... |
| Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects (CRC drug dependence series) by Caldwell |
| © 2008 BrightSurf.com |